THE POTENTIAL MODULATING IMPACT OF THE DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR, SITAGLIPTIN ON STREPTOZOTOCIN-NICOTINAMIDE-INDUCED DIABETIC NEPHROPATHY IN RATS
Abdel-Zaher, A., Abd-Allah, M., Mohammad, G., Abdel-Emam, R. (2022). THE POTENTIAL MODULATING IMPACT OF THE DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR, SITAGLIPTIN ON STREPTOZOTOCIN-NICOTINAMIDE-INDUCED DIABETIC NEPHROPATHY IN RATS. EKB Journal Management System, 45(2), 1013-1026. doi: 10.21608/bfsa.2022.271787
Ahmed O. Abdel-Zaher; Marwa G. Abd-Allah; Ghada H. Mohammad; Rania Abdel-Emam. "THE POTENTIAL MODULATING IMPACT OF THE DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR, SITAGLIPTIN ON STREPTOZOTOCIN-NICOTINAMIDE-INDUCED DIABETIC NEPHROPATHY IN RATS". EKB Journal Management System, 45, 2, 2022, 1013-1026. doi: 10.21608/bfsa.2022.271787
Abdel-Zaher, A., Abd-Allah, M., Mohammad, G., Abdel-Emam, R. (2022). 'THE POTENTIAL MODULATING IMPACT OF THE DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR, SITAGLIPTIN ON STREPTOZOTOCIN-NICOTINAMIDE-INDUCED DIABETIC NEPHROPATHY IN RATS', EKB Journal Management System, 45(2), pp. 1013-1026. doi: 10.21608/bfsa.2022.271787
Abdel-Zaher, A., Abd-Allah, M., Mohammad, G., Abdel-Emam, R. THE POTENTIAL MODULATING IMPACT OF THE DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR, SITAGLIPTIN ON STREPTOZOTOCIN-NICOTINAMIDE-INDUCED DIABETIC NEPHROPATHY IN RATS. EKB Journal Management System, 2022; 45(2): 1013-1026. doi: 10.21608/bfsa.2022.271787

THE POTENTIAL MODULATING IMPACT OF THE DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR, SITAGLIPTIN ON STREPTOZOTOCIN-NICOTINAMIDE-INDUCED DIABETIC NEPHROPATHY IN RATS

Bulletin of Pharmaceutical Sciences Assiut University
Volume 45, Issue 2, December 2022, Page 1013-1026  XML PDF (1000.94 K)
Document Type: Original Article
DOI: 10.21608/bfsa.2022.271787
View on SCiNiTO View on SCiNiTO
Authors
Ahmed O. Abdel-Zaher1; Marwa G. Abd-Allah1; Ghada H. Mohammad2; Rania Abdel-Emam email orcid 3
1Department of Pharmacology, Faculty of Medicine, Assiut University, Assiut 71526, Egypt
2Department of Pathology, Faculty of Medicine, Assiut University, Assiut 71526, Egypt
3Pharmacology Department, Faculty of Medicine, Assiut University, Assiut, Egypt
Abstract
The main risk factor for the onset and development of diabetic nephropathy (DN) is hyperglycemia. Kidney end-stage disease is brought on by DN, a significant microvascular consequence of diabetes. In this study, we evaluated the renoprotective potential of sitagliptin in a rat model of streptozotocin-nicotinamide-induced DN. Following the intraperitoneal treatment of rats with 110 mg/kg nicotinamide followed 15 min by 60 mg/kg streptozotocin, DN manifested in rats after 8 weeks. Fasting blood glucose, postprandial blood glucose, HbA1c, serum urea and creatinine, and urine albumin levels were assessed in control, DN, and DN rats treated with sitagliptin. Additionally, paraffin-embedded kidney segment histopathological assessment was carried out. The increased levels of fasting, postprandial blood glucose, and HbA1c were decreased with sitagliptin. Sitagliptin restored the changes in kidney structure and function brought on by DN. The findings suggest that sitagliptin could prevent DN by stringent glycemic management, restoring the kidneys' declining function and protecting their structure.
 
Keywords
Streptozotocin; Diabetic nephropathy; Sitagliptin; Kidney function and structure
Statistics
Article View: 139
PDF Download: 142